L Number	Hits	Search Text	DB	Time stamp
1	36	Murphy NEAR Patricia	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/21 16:34
2	11	(Murphy NEAR Patricia) and BRCA1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/21 16:35
3	20	((BRCA1 WITH sequence) and gene) and omi$1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/21 16:35
4	18	BRCA1 SAME "2201"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/21 16:35
-	2	("5654155").PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/23 13:00
-	1	("20020183268").PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/14 17:03
-	170	BRCA1 WITH sequence	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/27 17:57
-	164	(BRCA1 WITH sequence) and gene	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/14 17:08
-	116	Stommel	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/02 14:14
-	1	Stommel and brca1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/02 14:15
-	700	Durocher	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/02 14:15
-	11	(holt NEAR jeffrey) and brca1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/18 12:41
-	962	BRCA1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/18 12:51
-	13	BRCA1 and (thymidine WITH cytidine)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/18 12:52
-	6	(Murphy NEAR Patricia) and SEQ.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/19 10:46
-	49	(("5547839") or ("5510270") or ("6045997") or ("5561058") or ("5455934") or ("5891857") or ("6051379") or ("5858669") or ("4683202") or ("6130322") or ("5750400") or ("5911227") or ("5624803") or ("6083698") or ("5545531") or ("5948643") or ("5693473") or ("5589330") or ("5633134") or ("5726019") or ("5710001") or ("5753441") or ("5747282") or ("6033857") or ("6124104") or ("5756294")).PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/23 13:15

-	2	("5912127").PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/23 13:16
-	1	wo NEAR "9605306"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/27 16:52
-	1	WO NEAR "9605306"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/24 16:26
-	1	wo NEAR "9605306"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/03/02 13:58
-	17	Shattuck-Eidens WITH donna	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/03/02 18:09
-	21	holt NEAR jeffrey	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/03/02 18:09
-	14	Durocher and brca1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/03/02 18:09
-	18	BRCA1 SAME sequence SAME gene SAME omi$6	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/03/02 18:12
-	20	(US-6130322-$ or US-5654155-$ or US-6083698-$ or US-6048689-$ or US-5750400-$ or US-6432914-$ or US-5693473-$ or US-5709999-$ or US-6686163-$).did. or (US-20020183268-$ or US-20030022184-$ or US-20030096236-$ or US-20030235819-$ or US-20030027166-$).did. or (EP-1126034-$ or WO-9929903-$ or WO-9805677-$ or EP-705903-$).did. or (EP-705902-$).did.	USPAT; US-PGPUB; EPO; DERWENT	2004/03/02 18:13

```
=> d his

     (FILE 'HOME' ENTERED AT 17:03:13 ON 21 JUN 2004)

     FILE 'MEDLINE, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED AT
     17:03:33 ON 21 JUN 2004
L1        12897 S BRCA1?
L2            0 S L1 AND OMI2?
L3           55 S L1 AND OMI?
L4           34 DUP REM L3 (21 DUPLICATES REMOVED)
L5            1 S L4 AND PY<=1997
L6         9708 S L1 (L) (GENE OR SEQUCNE OR HAPLO? OR MUTANT?)
L7         2063 S L6 AND PY<=1997
L8            0 S L7 AND 2201
              E MURPHY PAT?/AU
L9            1 S E11
L10          14 S E9
L11          13 DUP REM L10 (1 DUPLICATE REMOVED)

=> d an ti so au ab pi l11 1-13

L11  ANSWER 1 OF 13  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2000:718247  CAPLUS
DN   133:262349
TI   Protein and cDNA sequences of the human BRCA1 genes and therapeutic and
     diagnostic uses thereof
SO   U.S., 56 pp., Cont.-in-part of U.S. 5,750,400.
     CODEN: USXXAM
IN   Murphy, Patricia D.; Allen, Antonette C. P.; Alvares,
     Christopher P.; Critz, Brenda S.; Olson, Sheri J.; Thurber, Denise; Zeng,
     Bin
AB   This invention provides protein and cDNA sequences for three human BRCA1
     genes, BRCA1omi1, BRCA1omi2, and BRCA1omi3 and their frequencies of
     occurrence.  Also disclosed is a method of determining the consensus sequence
     for any gene.  Another aspect of the invention is a method of identifying
     an individual having an increased genetic susceptibility to breast or
     ovarian cancer because they have inherited a causative mutation in their
     BRCA1 gene.  This invention is also related to a method of performing gene
     therapy with any of the isolated BRCA1 coding sequences.  This invention
     is further related to protein therapy with BRCAomi proteins or their
     functional equivalent
     PATENT NO.       KIND  DATE          APPLICATION NO.  DATE
     --------------   ----  --------      ---------------  --------
PI   US 6130322        A     20001010      US 1998-74476    19980506
     US 5654155        A     19970805      US 1996-598591   19960212
     US 5750400        A     19980512      US 1997-798691   19970212

L11  ANSWER 2 OF 13  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   1999:390442  CAPLUS
DN   131:40533
TI   Cancer susceptibility mutations of human BRCA1 gene and probes/primers for
     their detection
SO   PCT Int. Appl., 118 pp.
     CODEN: PIXXD2
IN   Olson, Sheri J.; Angelly, Tracy S.; Lawrence, Tammy; Lescallett, Jennifer
     L.; Murphy, Patricia D.; Allen, Antonette P.; Thurber, Denise
     B.; White, Marga B.; Zeng, Bin; Sadzewicz, Lisa K.
AB   New mutations have been found in the human BRCA1 gene.  The mutations are
     located at nucleotide nos. 421-2, 815, 903, 926, 1506, 2034, 2428, 3888,
     3904, 4164, 4643, 5053, 5150, 5210, or 5396+40 of the gene sequence of
     BRCA1.  A process for identifying a sequence variation in a BRCA1
     polynucleotide sequence is disclosed.  The identification process includes
     allele specific sequence-based assays of known sequence variations.
     Fifty-five oligonucleotide probes and/or primers specific for the normal
     and mutant alleles are provided.  The methods can be used for efficient,
     and accurate detection of a mutation in a test BRCA1 gene sample.
     PATENT NO.       KIND  DATE          APPLICATION NO.  DATE
     --------------   ----  --------      ---------------  --------
```

PI WO 9929903 A2 19990617 WO 1998-US25916 19981207
WO 9929903 A3 19990902
W: CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
US 6083698 A 20000704 US 1997-988706 19971211
CA 2312273 AA 19990617 CA 1998-2312273 19981207
EP 1036199 A2 20000920 EP 1998-960779 19981207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2001526050 T2 20011218 JP 2000-524474 19981207

L11 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:139957 CAPLUS
DN 130:205946
TI Coding sequence haplotypes and polymorphisms of human BRCA2 gene
SO PCT Int. Appl., 226 pp.
CODEN: PIXXD2
IN **Murphy, Patricia D.**; White, Marga B.; Rabin, Mark B.; Olson, Sheri J.; Yoshikawa, Matthew; Jackson, Geoffrey M.; Eskandari, Tara; Schryer, Brenda; Park, Michael
AB Five DNA and protein sequences have been determined for the BRCA2 gene, as have been 10 polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2(omi1-5) and the 10 polymorphic sites will provide accuracy and reliability for genetic testing. One skilled in the art will be able to avoid misinterpretations of changes in the gene and/or protein sequence, determine the presence of a normal sequence, and of mutations of BRCA2. This invention is also related to a method of performing gene therapy with BRCA2(omi1-5) coding sequences or fragments thereof. This invention is further related to protein therapy with BRCA2(omi1-5) proteins or their functional equivalent

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9909164	A1	19990225	WO 1998-US16905	19980814
W: AU, CA, IL, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9892928	A1	19990308	AU 1998-92928	19980814
EP 994946	A1	20000426	EP 1998-945756	19980814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001514887	T2	20010918	JP 2000-509828	19980814

L11 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:113846 CAPLUS
DN 130:178314
TI Determining the frequencies of common functional alleles of a gene in a population and therapeutic uses of the information
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
IN **Murphy, Patricia D.**
AB Methods for identifying the frequencies of alleles of a given gene in a population (functional allele profiles) are disclosed. Functional allele profiles comprise the commonly occurring alleles in a population, and the relative frequencies at which such alleles of a given gene occur. Functional allele profiles are useful in treatment and diagnosis of diseases, for genetic and pharmacogenetic applications and for evaluating the degree to which the gene(s) are under selective pressure. Anal. of sequence polymorphisms at the MSH2, MLH1, and BRCA1 genes in normal populations using PCR to amplify subsequences and sequence anal. is described. The use of allele frequency information to minimize the possibility of adverse effects to drugs is demonstrated by analyzing polymorphisms at the human glucose-6-phosphate dehydrogenase gene. The use of allele frequencies at a number of oncogenes to estimate the likely effectiveness of tamoxifen in chemoprophylaxis of breast cancer is also discussed.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9906598	A2	19990211	WO 1998-US16574	19980804

WO 9906598 A3 19990429
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9887768 A1 19990222 AU 1998-87768 19980804

L11 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:685006 CAPLUS
DN 129:299016
TI Methods for identifying variations in polynucleotide sequences
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
IN **Murphy, Patricia D.**; White, Marga B.
AB A step-wise integrated process for identifying sequence variations in polynucleotide sequences is disclosed. The identification process is composed of three stages, including allele specific hybridization assays of known sequence variations (Stage I), sequence variation locating assays (Stage II), and direct sequencing (Stage III). The methods can be used for efficient and accurate detection of mutations in any test gene sample. Thus, a BRCA1 gene sample was analyzed for 8 mutations using allele-specific oligonucleotides. The test gene was found to be neg. for the eight mutations. Exon 11 of the test gene was then analyzed using a protein truncation assay. A shorter-than-normal protein was obtained in one case. Sequencing of the coding region in the appropriate area indicated that a nonsense mutation (C3508G) resulting in a premature termination codon (TCA to TGA) had occurred.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9844157	A2	19981008	WO 1998-US6002	19980326
WO 9844157	A3	19981230		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 6048689	A	20000411	US 1997-825487	19970328
AU 9867781	A1	19981022	AU 1998-67781	19980326

L11 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:112376 CAPLUS
DN 128:189161
TI Susceptibility mutations in human gene BRCA1 for breast and ovarian cancer and oligonucleotide probes and primers for their detection
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
IN **Murphy, Patricia D.**; Allen, Antonette C.; White, Marga B.; Olson, Sheri J.; Zeng, Bin
AB New mutations have been found in the BRCA1 gene, at positions 943 (designated 943ins10), 944, 2799 (2799delAA), 2800, 4158 (4158delAG), 4159, and 5053 (5053delG) of the gene sequence reported in GenBank Accession Number U14680. Allele-specific oligonucleotide probes and/or amplification primers are designed to detect these mutations. The invention provides a method for diagnosing persons at risk of developing breast or ovarian cancer. The invention also provides a further tool with which to characterize tumors.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9805677	A1	19980212	WO 1997-US13654	19970804

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9740509	A1	19980225	AU 1997-40509	19970804	

L11 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:527733 CAPLUS
DN 127:186634
TI Consensus sequence of the human BRCA1 gene and its normal polymorphisms
SO U.S., 35 pp.
CODEN: USXXAM
IN **Murphy, Patricia D.**; Allen, Antonette C.; Alvares, Christopher P.; Critz, Brenda S.; Olson, Sheri J.; Schelter, Denise B.; Zeng, Bin
AB A consensus DNA sequence was determined for the human BRCA1 gene based on PCR amplification of exons and dideoxy sequencing of the BRCA1 gene from 5 normal individuals. Seven polymorphic sites and their rates of occurrence were detected in normal BRCA1 genes. The consensus gene BRCA1omi and the 7 polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene, determine the presence of a normal gene, and of mutations, and to classify tumors. A 2-bp mutation (3888delGA) in the BRCA1 gene was detected using PCR primers for segment K of exon 11 using the BRCA1omi and 7 polymorphisms for reference

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5654155	A	19970805	US 1996-598591	19960212
CA 2218251	AA	19970814	CA 1997-2218251	19970212
WO 9729213	A1	19970814	WO 1997-US3038	19970212
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9719778	A1	19970828	AU 1997-19778	19970212
EP 820526	A1	19980128	EP 1997-907894	19970212
EP 820526	B1	20011107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 5750400	A	19980512	US 1997-798691	19970212
JP 11503924	T2	19990406	JP 1997-528770	19970212
BR 9702080	A	19991228	BR 1997-2080	19970212
EP 1126034	A2	20010822	EP 2001-107300	19970212
EP 1126034	A3	20010829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 208425	E	20011115	AT 1997-907894	19970212
PT 820526	T	20020531	PT 1997-907894	19970212
ES 2170366	T3	20020801	ES 1997-907894	19970212
US 6130322	A	20001010	US 1998-74476	19980506
US 2002183268	A1	20021205	US 2000-734672	20001213
US 2003096236	A1	20030522	US 2001-923327	20010808
US 2003022184	A1	20030130	US 2001-982828	20011022